BC Innovations | Aug 22, 2019
Tools & Techniques

Digital makes its mark on cognition

Digital biomarkers of cognitive decline could be the antidote to the slop in the subjective tests on which clinical neurology programs often hinge. With proof of concept established in small clinical trials and bigger readouts...
BioCentury | Jun 13, 2019
Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders. New investors Polaris Partners,...
BC Week In Review | Jan 11, 2019
Clinical News

BlackThorn deprioritizing MDD compound after Phase IIa miss

BlackThorn Therapeutics Inc. (San Francisco, Calif.) said it will deprioritize development of BTRX-246040 (formerly LY-2940094) to treat major depressive disorder (MDD) after the compound missed the primary and secondary endpoints in a Phase IIa trial....
BC Week In Review | Aug 10, 2018
Company News

BlackThorn licenses Yale's neuroimaging tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
BC Extra | Aug 6, 2018
Company News

BlackThorn licenses Yale's neuroimaging drug discovery tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
BC Week In Review | Jun 8, 2018
Clinical News

BlackThorn brings KOR antagonist into clinic

BlackThorn Therapeutics Inc. (San Francisco, Calif.) began a Phase I trial evaluating up to seven single and multiple ascending doses of BTRX-335140 to assess dose exposure and safety in about 90 healthy volunteers. The company...
BioCentury | Jul 28, 2017
Product Development

Circuit logic

BlackThorn Therapeutics Inc. has begun the first of a series of studies that will test whether it can solve a tough problem in neurological drug development: the tendency of heterogeneity among patients with the same...
Items per page:
1 - 7 of 7